Cargando…

Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study

BACKGROUND: Immunocompromised cancer patients are presumed to be at high risk of developing COVID-19 infection. Predisposing factors to contracting COVID-19 and to severe outcomes have been described in registries but were not compared between solid tumors and hematological malignancies. METHOD: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goudsmit, Anouk, Cubilier, Edouard, Meert, Anne-Pascale, Aftimos, Philippe, Stathopoulos, Konstantinos, Spilleboudt, Chloe, Loizidou, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043836/ https://www.ncbi.nlm.nih.gov/pubmed/33851236 http://dx.doi.org/10.1007/s00520-021-06175-z

Ejemplares similares

ABCL-013: Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study
por: Goudsmit, Anouk, et al.
Publicado: (2021)

Poster: ABCL-013: Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study
por: Goudsmit, Anouk, et al.
Publicado: (2021)

SARS‐CoV‐2 infection in hematological patients during allogenic stem cell transplantation: A double case report
por: Alexandra, Van Uytvanck, et al.
Publicado: (2021)

PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients
por: Gueuning, Candice, et al.
Publicado: (2022)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis
por: Martins-Branco, Diogo, et al.
Publicado: (2022)

437. A Single-Center Experience of Solid versus Hematologic Malignancies in People Living with HIV
por: Daoud, Nour A, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?
por: Zojer, Niklas
Publicado: (2021)

Five Cases Report of Solid Tumor Synchronously with Hematologic Malignancy
por: Cui, Yuehong, et al.
Publicado: (2012)

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
por: Federico, Mario, et al.
Publicado: (2011)

Detection and Identification of Hematologic Malignancies and Solid Tumors by an Electrochemical Technique
por: Wang, Yujie, et al.
Publicado: (2016)

Nutritional status of children and adolescents at diagnosis of hematological and solid malignancies
por: Lemos, Priscila dos Santos Maia, et al.
Publicado: (2014)

Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies
por: Mancini, Stéphane J.C., et al.
Publicado: (2021)

Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies
por: Allegra, Alessandro, et al.
Publicado: (2022)

Hematologic malignancies following immune checkpoint inhibition for solid tumors
por: van Eijs, Mick J. M., et al.
Publicado: (2022)

PPM1D in Solid and Hematologic Malignancies: Friend and Foe?
por: Zhang, Linda, et al.
Publicado: (2022)

Recent Prospective in CAR T-Based Therapy for Solid and Hematological Malignancies
por: Marei, Hany E., et al.
Publicado: (2023)

Red blood cell transfusion in the resuscitation of septic patients with hematological malignancies
por: Mirouse, Adrien, et al.
Publicado: (2017)

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
por: Ellis, Leigh, et al.
Publicado: (2010)

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors
por: Lin, Swan, et al.
Publicado: (2019)

Acute Respiratory Failure in Patients with Hematologic and Solid Malignancies: Global Approach
por: Sethi, Sakshi, et al.
Publicado: (2017)

Thirty-Two Case Reports of Synchronous Hematological Malignancy and Solid Tumor
por: Liu, Sha, et al.
Publicado: (2019)

Risk of infection associated with targeted therapies for solid organ and hematological malignancies
por: Ruiz-Camps, Isabel, et al.
Publicado: (2021)

The emerging landscape of exosomal CircRNAs in solid cancers and hematological malignancies
por: Zhou, Qinfeng, et al.
Publicado: (2022)

Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia – a single center analysis
por: Sandner, Anne-Sophie, et al.
Publicado: (2019)

Telomerase Activation in Hematological Malignancies
por: Ropio, Joana, et al.
Publicado: (2016)

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies
por: Wiestner, Adrian
Publicado: (2022)

Outcomes of Patients with Hematologic Malignancies and COVID-19: Perspective of a Large Hematology Center in Greece
por: Spyridis, Nikolaos, et al.
Publicado: (2021)

Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2021)

HMGA Proteins in Hematological Malignancies
por: Minervini, Angela, et al.
Publicado: (2020)

Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
por: McBride, Ali, et al.
Publicado: (2012)

Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
por: Tumino, Nicola, et al.
Publicado: (2021)

The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies
por: Shaw, Jaime L., et al.
Publicado: (2021)

(1, 3)-β-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies
por: Azoulay, Elie, et al.
Publicado: (2016)

Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience
por: Galvez, Carlos, et al.
Publicado: (2020)

Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2
por: Santarelli, Ignacio Martín, et al.
Publicado: (2023)

New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
por: Andreozzi, Fabio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q9gu7quf1q61m46f4brianau6c